Genetic validation of ApoA-I in sepsis by ABIONYX Pharma

Biotechnology company ABIONYX Pharma announces a major breakthrough with the publication of a groundbreaking study in the journal Nature. This study demonstrates for the first time a genetic link between elevated plasma levels of apolipoprotein AI (ApoA-I) and a significant reduction in the incidence and mortality of sepsis.

Conducted on 442,601 participants, the study established that each increase in the standard deviation of ApoA-I levels reduced the incidence of sepsis by 13% and 28-day mortality by 27%. This positions ApoA-I as the first recognized causal protective factor in the treatment of sepsis, thus opening new therapeutic perspectives.

With this discovery, ABIONYX Pharma strengthens its strategic position in the development of innovative treatments for this deadly pathology.